溴隐亭治疗泌乳素大腺瘤的临床观察

Efficacy and safety of bromocriptine as first line treatment for macroprolactinoma

目的:探讨溴隐亭治疗泌乳素大腺瘤的方法、效果及不良反应。方法:回顾性分析单纯溴隐亭治疗9例泌乳素大腺瘤的长期随访结果。结果:溴隐亭的开始剂量为1.25～2.5 mg.d-1、分2～3次口服,在6个月内缓慢增至5～15 mg.d-1。平均随访58.3个月,最后随访时血泌乳素(prolactine,PRL)恢复正常8例(88.89%)、肿瘤体积平均缩小(81.3±23.9)%。治疗期间大部分原发症状好转,出现头晕2例、脑脊液漏1例。结论:溴隐亭单药治疗泌乳素大腺瘤能明显降低血PRL、缩小肿瘤体积及改善临床症状,且不良反应少。

OBJECTIVE To investigate the methods, efficacy and safety of bromocriptine as first line treatment for macrop rolactinoma. METHODS Retrospectivly analyse the long-term follow-up datas of 9 cases of macroprolactinoma treated with bromocriptine. RESULTS Bromocriptine was initiated with a dose of 0. 625- 1.25 mg daily given in twice or thrice, and a dose generally of 5-15 mg daily was gradually reached in 6 months. In the mean follow-up period of 58. 3 months, 8 patients have normalized their prolactin levels, the mean reduction in tumor volume was （81.3 ± 23.9）%0. Most of the symptoms caused by tumor or hyperprolactinemia were improved, and 2 cases of dizziness and 1 case of cerehrospinal fluid leakage happened during the therapy. CONCLUSION Bromocriptine monotherapy is effective and well tolerated for macroprolactinoma.